ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 134

Co-Existence of Gout in Rheumatoid Arthritis: It Does Happen!  A Population Based Study

Adlene Jebakumar1, Cynthia S. Crowson2, P. Deepak Udayakumar1 and Eric L. Matteson1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Department of Health Sciences Research, Mayo Clinic, Rochester, MN

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Gout and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Metabolic and Crystal Arthropathies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Even though there are a few cases in the literature reporting co-existence of gout and rheumatoid arthritis (RA), it has been a long time popular belief that gout does not occur in patients with RA. We aimed to assess the occurrence, clinical presentation, and possible risk factors for gout in patients with RA.

Methods: We retrospectively reviewed a population-based incidence cohort of patients who fulfilled 1987 ACR criteria for RA in 1980-2007. All subjects were longitudinally followed through their complete community medical records until death, migration, or April 2012. Gout was defined using the physician diagnosis, along with typical monosodium urate crystal positivity in synovial fluid or the 1977 ARA clinical criteria for gout. We excluded the patients with pseudogout, hyperuricemia without gout, septic arthritis, traumatic arthritis, and RA initially misdiagnosed as having gout. Cumulative incidence of gout in RA adjusted for the competing risk of death was estimated. Cox models were used to assess risk factors for gout in RA.

Results: The study population included 813 patients, 537 (66%) were rheumatoid factor positive; 33% had rheumatoid nodules, and 53% had erosive joint disease. During 9771 total person-years of follow-up (mean 12.0 years per RA patient), 22 patients developed gout by clinical criteria. The great toe was the most common site of gout (12 of 22 patients).  The 25 year cumulative incidence of gout diagnosed by clinical criteria was 5.3%. Typical intracellular monosodium urate crystals were present in 9 of 22 patients with acute gout; all had developed gout after the RA incidence date. The 25 year cumulative incidence of gout diagnosed by clinical criteria including presence of urate crystals is 1.3%. The prevalence of gout in RA on Jan 1, 2008 was 1.9% (11 of 582 patients) as opposed to expected prevalence of 5.2% (or 30 patients) based on National Health and Nutrition Examination Survey (NHANES) data using age and sex specific prevalence rates.

Risk factors for gout in RA were: older age (hazard ratio [HR] 1.5 per 10 year increase; p  = 0.04), male sex (HR 3.18; p = 0.03) and obesity (HR 3.5; p = 0.03).  The presence of erosive RA joint disease reduced the risk of gout (HR 0.24; p = 0.03). Gout has become more common in patients diagnosed with RA in recent years (1995-2007) than in previous years (1980-1994; HR 5.6; p = 0.007).

Conclusion: Gout does occur in patients with RA though at a lower rate than in the general population, with a minimum/maximum cumulative incidence of 1.3/5.3%. Risk factors for gout in RA generally mirror those in the general population.


Disclosure:

A. Jebakumar,
None;

C. S. Crowson,
None;

P. D. Udayakumar,
None;

E. L. Matteson,

Centocor, Inc./Johnson and Johnson,

2,

Genentech and Biogen IDEC Inc.,

2,

Hoffmann-La Roche, Inc.,

2,

Human Genome Sciences, Inc.,

2,

Pfizer Inc,

2,

Novartis Pharmaceutical Corporation,

2,

Roche Pharmaceuticals,

2,

UCB Group,

2,

Centocor, Inc.,

5,

Horizon Pharma,

5,

Novartis Pharmaceutical Corporation,

5.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/co-existence-of-gout-in-rheumatoid-arthritis-it-does-happen-a-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology